HMD
vs
S
S&P/ASX 300
HMD
Over the past 12 months, HMD has significantly outperformed S&P/ASX 300, delivering a return of +100% compared to the S&P/ASX 300's +7% growth.
Stocks Performance
HMD vs S&P/ASX 300
Performance Gap
HMD vs S&P/ASX 300
Performance By Year
HMD vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Hera Med Ltd
Glance View
HeraMED Ltd. engages in the development and production of pregnancy monitoring solutions for home and professional use. The company offers hardware solutions supported by software applications. Its product HeraBEAT, is a medical-grade, clinically-validated and connected Ultrasound Fetal Doppler device predominantly for use by an expectant mother to self-monitor her fetus’ heart rate (FHR) at home. HeraBEAT communicates with any smartphone (iOS/Android) through Bluetooth Low Energy (BLE). A mother can hold or strap the HeraBEAT device to her abdomen, and the collected data is transmitted to her smartphone where the relevant readings are displayed through an interface. The firm also develops a service model which includes a homecare pregnancy solution. In addition, the Company develops artificial intelligence (AI), machine-learning, computerized algorithms to monitor and analyze the data so a healthcare professional or home user is informed of the wellbeing of the fetus.
